Antikor Biopharma
PrivateLast Round
Grant
Nov 1, 2024
Total Funding Raised
$1.51M
Company Overview
Antikor Biopharma operates in Healthcare & Life Sciences and is based in Stevenage. Its latest recorded funding round was a Grant round in April 2022.
Antikor Biopharma is a biotechnology company that specializes in the discovery and development of small-format Antibody Fragment Drug Conjugates (FDCs) for the treatment of solid tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Antikor Biopharma Comparables
Compare Antikor Biopharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Crescendo Biologics Ltd. | 75% | |
| Avacta Group | 70% | |
| Bicycle Therapeutics | 69% |
For institutional investors. Book with your work email.
Antikor Biopharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Nov 1, 2024 | ||||
| Grant | Apr 1, 2022 | ||||
| VC Round | Jul 31, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Antikor Biopharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Essex Bio-Technology | VC Round |
| Innovate UK | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 20, 2026
Monthly visitors increased 31% MoM.
- Apr 4, 2026
Monthly visitors increased 121% MoM.
For institutional investors. Book with your work email.
Antikor Biopharma Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Antikor Biopharma's valuation, stock price, and market status.
Is Antikor Biopharma a public or private company?
Antikor Biopharma is a private company.
What is the current stock price of Antikor Biopharma?
Antikor Biopharma is a private company, so its shares have no public market price. Caplight tracks Antikor Biopharma's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Antikor Biopharma worth (valuation)?
Valuation information for Antikor Biopharma is not publicly available.
Can I buy Antikor Biopharma stock?
Antikor Biopharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Antikor Biopharma's last funding round?
Antikor Biopharma's most recent funding round was Grant on November 1, 2024.
Who are the main investors in Antikor Biopharma?
Key investors in Antikor Biopharma include Essex Bio-Technology.
Will Antikor Biopharma IPO soon?
No public IPO plans have been announced for Antikor Biopharma.
How can I track Antikor Biopharma secondary market activity?
Caplight tracks bids, offers, and trades in Antikor Biopharma's shares on secondary markets.